bms-202

BMS-202 (PD1-PDL1 inhibitor 2) is a non-peptide PD-1/PD-L complex inhibitor with an IC50 of 18 nM and a KD of 8 μM. BMS-202 binds to PD-L1 with high affinity and blocks human PD-1/PD-L interactions, exhibiting antitumor activity.

N-deacetylated BMS-202 is an inhibitor of PD-1/PD-L1 interactions and has potential anticancer activity for cancer research.

BMS202 hydrochloride (1675203-84-5(free base)) (PD-1/PD-L1 inhibitor 2 hydrochloride) is a small-molecule PD-1/PD-L1 interaction inhibitor (IC50: 18 nM). Biophysical studies demonstrate that BMS202 binds directly to PD-L1. Binding of BMS202 promotes PD-L1 dimerisation and blocks the PD-L1/ PD1 interaction.

TDO-IN-2 is an orally active TDO inhibitor with an IC50 of 1.25 μM. It exhibits antitumor activity in a Hepa1-6 liver cancer allograft mouse model. Additionally, TDO-IN-2 works synergistically with PD-1/PD-L1 inhibitor BMS-202, making it useful for studying tumor immune tolerance.

E3 Ligase Ligand PG serves as an E3 ligase ligand capable of recruiting the CRBN protein. It demonstrates strong binding affinity with CRBN, exhibiting an IC50 of 2.191 μM. Furthermore, E3 Ligase Ligand PG can be linked via a linker to BMS-202 to form PROTAC, PROTACPD-L1degrader-1.